Company intelligence / Profile preview
Nanocarry Therapeutics
Ness Ziona, Central District, Israelnanocarry.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Nanocarry’s lead program, AxS007, is in preclinical development and was selected by the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory for comprehensive preclinical characterization. The company’s proprietary AxS platform enables a 50-fold increase in brain delivery of therapeutic antibodies with up to 8x the payload compared to conventional approaches, aiming to overcome the blood-brain barrier for effective treatment of CNS diseases and brain cancers
- Therapeutic areas
- OncologyNeurology
- Modalities
- Bioengineered nanoparticlesAntibodiesSmall molecules (as payloads)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
U.S. National Cancer Institute/Nanotechnology Characterization Laboratory for preclinical characterization support
Beyond the preview
Go deeper on Nanocarry Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanocarry Therapeutics.